Nexhyon represents the next generation of M.hyo vaccines based on recombinant biotechnology.
The inactivated Nexhyon strain is both the target active substance and, at the same time, the expression system. There is no undesired residual DNA and no undesired proteins coming from the expression system or cell cultures.
This inactivation process results in spheres of the Nexhyon strain with the embedded PCV2 capsid protein. As no chemical inactivating agents are used, the antigenic fraction is presented in its native form.
The inactivated Nexhyon strain is complemented with an ideal adjuvant to set its power free: a light liquid paraffin special formula, specifically designed for intradermal delivery.